Non‐nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 16 (1), 1-14
- https://doi.org/10.7448/ias.16.1.18567
Abstract
Human immunodeficiency virus (HIV) type-1 non-nucleoside and nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy (HAART) in the clinical management of acquired immune deficiency syndrome (AIDS)/HIV infection. First-generation NNRTIs, nevirapine (NVP), delavirdine (DLV) and efavirenz (EFV) are drugs with a low genetic barrier and poor resistance profile, which has led to the development of new generations of NNRTIs. Second-generation NNRTIs, etravirine (ETR) and rilpivirine (RPV) have been approved by the Food and Drug Administration and European Union, and the next generation of drugs is currently being clinically developed. This review describes recent clinical data, pharmacokinetics, metabolism, pharmacodynamics, safety and tolerability of commercialized NNRTIs, including the effects of sex, race and age differences on pharmacokinetics and safety. Moreover, it summarizes the characteristics of next-generation NNRTIs: lersivirine, GSK 2248761, RDEA806, BILR 355 BS, calanolide A, MK-4965, MK-1439 and MK-6186. This review presents a wide description of NNRTIs, providing useful information for researchers interested in this field, both in clinical use and in research.Keywords
This publication has 99 references indexed in Scilit:
- Antiviral Activity and In Vitro Mutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase InhibitorAntimicrobial Agents and Chemotherapy, 2012
- LC–MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studiesJournal of Chromatography B, 2010
- Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve SubjectsAntimicrobial Agents and Chemotherapy, 2010
- Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of LersivirineAntimicrobial Agents and Chemotherapy, 2010
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Antimicrobial Agents and Chemotherapy, 2010
- Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretroviralsAIDS, 2010
- Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to EtravirineAntimicrobial Agents and Chemotherapy, 2009
- Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorAntimicrobial Agents and Chemotherapy, 2009
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- Pharmacokinetics of BILR 355 after Multiple Oral Doses Coadministered with a Low Dose of RitonavirAntimicrobial Agents and Chemotherapy, 2009